Literature DB >> 2943898

Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.

J E Arrowsmith, S F Campbell, P E Cross, J K Stubbs, R A Burges, D G Gardiner, K J Blackburn.   

Abstract

A series of dihydropyridines substituted at the 2-position by basic side chains are described and their potencies as calcium antagonists listed. One compound, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5- methoxycarbonyl-6-methyl-1,4-dihydropyridine (17, amlodipine) was found to be comparable in potency to nifedipine and to have an elimination half-life of 30 h in dogs. Oral bioavailability approached 100%, and hemodynamic responses were gradual in onset and long-lasting in effect. The two enantiomers have been prepared, and the bulk of the activity was found to reside with the (-) isomer, 18. X-ray crystallographic studies, carried out on a close analogue of 17, suggest the existence of a weak hydrogen bond between the side-chain oxygen and the proton on the ring nitrogen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943898     DOI: 10.1021/jm00159a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Synthesis and calcium channel antagonist activity of 3-arylmethyl 5-isopropyl 1,4-dihydro-2,6-dimethyl-4-(pyridyl)-3,5-pyridinedicarboxylates.

Authors:  M R Akula; W C Matowe; M W Wolowyk; E E Knaus
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

2.  Cyclodextrine screening for the chiral separation of amlodipine enantiomers by capillary electrophoresis.

Authors:  Gabriel Hancu; Monica Budău; Lajos Kristóf Kántor; Anca Cârje
Journal:  Adv Pharm Bull       Date:  2015-03-05

3.  Distinct properties of amlodipine and nicardipine block of the voltage-dependent Ca2+ channels Cav1.2 and Cav2.1 and the mutant channels Cav1.2/dihydropyridine insensitive and Cav2.1/dihydropyridine sensitive.

Authors:  Min Lin; Oluyemi Aladejebi; Gregory H Hockerman
Journal:  Eur J Pharmacol       Date:  2011-09-02       Impact factor: 4.432

Review 4.  Pharmacokinetics of calcium antagonists under development.

Authors:  D R Abernethy; J B Schwartz
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

5.  Pharmacokinetics, metabolism, and in vivo efficacy of the antimalarial natural product bromophycolide A.

Authors:  Margaret E Teasdale; Jacques Prudhomme; Manuel Torres; Matthew Braley; Serena Cervantes; Shanti C Bhatia; James J La Clair; Karine Le Roch; Julia Kubanek
Journal:  ACS Med Chem Lett       Date:  2013-10-10       Impact factor: 4.345

Review 6.  Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors.

Authors:  Rebecca Chaplin; Lyna Thach; Morley D Hollenberg; Yingnan Cao; Peter J Little; Danielle Kamato
Journal:  J Cell Commun Signal       Date:  2017-02-06       Impact factor: 5.782

7.  The interactions of 1,4-dihydropyridines bearing a 2-(2-aminoethylthio)methyl substituent at voltage-dependent Ca2+ channels of smooth muscle, cardiac muscle and neuronal tissues.

Authors:  Y W Kwon; Q Zhong; X Y Wei; W Zheng; D J Triggle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

8.  Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of racemic drugs and enantiomers.

Authors:  P A Soons; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Structural model for dihydropyridine binding to L-type calcium channels.

Authors:  Denis B Tikhonov; Boris S Zhorov
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

10.  In vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine.

Authors:  P Deloron; L K Basco; B Dubois; C Gaudin; F Clavier; J Le Bras; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.